Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + pemetrexed + bevacizumab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Cisplatin + pemetrexed + bevacizumab is a combination chemotherapy regimen used primarily as first-line treatment for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and unresectable malignant pleural mesothelioma. Cisplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis. Pemetrexed is an antifolate that inhibits enzymes involved in purine and pyrimidine synthesis, disrupting DNA replication and cell division. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), thereby inhibiting angiogenesis required for tumor growth. This combination has demonstrated favorable efficacy and manageable toxicity profiles in clinical studies, with maintenance therapy using pemetrexed plus bevacizumab often following induction cycles[1][2][5][6].
- Brand names
- AvastinPlatinolAlimta
- Other names
- BEV-PEM/CISPCB regimen
02
Targets
GART (GAR transformylase)TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)VEGFA (Vascular endothelial growth factor A)DNA
Beyond the preview
Go deeper on cisplatin + pemetrexed + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + pemetrexed + bevacizumab.